Cowen initiated coverage on CTI BioPharma with a new price target
$CTIC
Biotechnology: Pharmaceutical Preparations
Health Care
Cowen initiated coverage of CTI BioPharma with a rating of Outperform and set a new price target of $10.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/17/2022 | $13.00 | Outperform | SVB Leerink |
| 9/1/2022 | $13.00 | Buy | Jefferies |
| 7/7/2022 | $10.00 | Outperform | Cowen |
| 3/2/2022 | $4.00 → $5.00 | Market Outperform | JMP Securities |
| 3/2/2022 | $5.00 → $8.00 | Buy | Needham |
| 12/1/2021 | $6.00 → $5.00 | Buy | Needham |
| 8/9/2021 | $7.00 | Buy | BTIG Research |
4 - CTI BIOPHARMA CORP (0000891293) (Issuer)
4 - CTI BIOPHARMA CORP (0000891293) (Issuer)
4 - CTI BIOPHARMA CORP (0000891293) (Issuer)
Transaction Price of $9.10 Per Share Represents Compelling 89% Premium to CTI's Closing Stock Price on May 9, 2023 SEATTLE, May 10, 2023 /PRNewswire/ -- CTI BioPharma (NASDAQ:CTIC) ("CTI"), a commercial biopharmaceutical company focused on the development and commercialization of novel targeted therapies for blood-related cancers, today announced that it has entered into a definitive agreement under which Swedish Orphan Biovitrum AB (STO: SOBI) ("Sobi"), a global healthcare leader in hematology, immunology and specialty care, will acquire CTI for $9.10 per share of common stock in an all-cash transaction, representing an implied equity value of approximately $1.7 billion. The transaction wi
SEATTLE, May 1, 2023 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC), a commercial biopharmaceutical company focused on the development and commercialization of novel targeted therapies for blood-related cancers, today announced that its first quarter 2023 financial results will be reported on Thursday, May 11, 2023, after the close of the financial markets. Management will host a webcast and conference call at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update. Registration for the live and archived webcast may be accessed on the CTI BioPharma website under the Investors & Media section: Events and Presentations. To participate via telephone, please register in a
– Growing physician awareness and usage of VONJO® (pacritinib) drove quarterly double-digit revenue growth – – VONJO® net product revenue exceeded year-end goal with a total of $54 million for 2022 and $21.1 million in the fourth quarter, a 16% increase compared to the third quarter – – ASH 2022 oral presentation featured new data on pacritinib's ACVR1 inhibition and anemia benefit in myelofibrosis patients – – Management to host webcast and conference call at updated time today at 8:30 a.m. ET – SEATTLE, March 6, 2023 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC), a commercial biopharmaceutical company focused on the development and commercialization of novel targeted therapies for bloo
SVB Leerink initiated coverage of CTI BioPharma with a rating of Outperform and set a new price target of $13.00
Jefferies initiated coverage of CTI BioPharma with a rating of Buy and set a new price target of $13.00
Cowen initiated coverage of CTI BioPharma with a rating of Outperform and set a new price target of $10.00
JMP Securities analyst Reni Benjamin maintains CTI BioPharma (NASDAQ:CTIC) with a Market Perform.
The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies. The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down. When compared to a stock's price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the RSI is above 70. Here’s the latest list of major overbought players in this sector. Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) Cerevel Therapeutics appointed Susan Altschuller, as Chief Financial Officer. The company’s stock has a 52-week high of $41.4
Upgrades According to Macquarie, the prior rating for Lufax Holding Ltd (NYSE:LU) was changed from Underperform to Outperform. For the fourth quarter, Lufax Holding had an EPS of $0.05, compared to year-ago quarter EPS of $0.19. The current stock performance of Lufax Holding shows a 52-week-high of $7.05 and a 52-week-low of $1.26. Moreover, at the end of the last trading period, the closing price was at $1.64. Barrington Research upgraded the previous rating for Warner Bros. Discovery Inc (NASDAQ:WBD) from Market Perform to Outperform. For the first quarter, Warner Bros. Discovery had an EPS of $0.44, compared to year-ago quarter EPS of $0.69. The current stock performance of Warner Bros
SC 13D/A - CTI BIOPHARMA CORP (0000891293) (Subject)
SC 13G - CTI BIOPHARMA CORP (0000891293) (Subject)
SC 13G - CTI BIOPHARMA CORP (0000891293) (Subject)
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER OF OR THE SOLICITATION OF AN OFFER TO BUY SECURITIES IN ANY JURISDICTION. STOCKHOLM, June 24, 2023 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) (STO: SOBI) announced today that it has, through its indirect wholly owned subsidiary Cleopatra Acquisition Corp. (Cleopatra), successfully completed its tender offer to purchase all outstanding shares of common stock of CTI BioPharma Corp. (NASDAQ:CTIC) (CTI), at a price of USD 9.10 per sh
SEATTLE, May 30, 2023 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) ("CTI"), a commercial biopharmaceutical company focused on the development and commercialization of novel targeted therapies for blood-related cancers, today announced that it has cancelled the 2023 Annual Meeting of Stockholders (the "Annual Meeting") which was scheduled for June 21, 2023, and has withdrawn the proposals to have been submitted to stockholders at the Annual Meeting. The Annual Meeting has been cancelled due to the ongoing tender offer by Swedish Orphan Biovitrum AB (publ) (STO: SOBI) ("Sobi") to acquire all of the outstanding common stock of CTI pursuant to the Agreement and Plan of Merger, dated as of M
Transaction Price of $9.10 Per Share Represents Compelling 89% Premium to CTI's Closing Stock Price on May 9, 2023 SEATTLE, May 10, 2023 /PRNewswire/ -- CTI BioPharma (NASDAQ:CTIC) ("CTI"), a commercial biopharmaceutical company focused on the development and commercialization of novel targeted therapies for blood-related cancers, today announced that it has entered into a definitive agreement under which Swedish Orphan Biovitrum AB (STO: SOBI) ("Sobi"), a global healthcare leader in hematology, immunology and specialty care, will acquire CTI for $9.10 per share of common stock in an all-cash transaction, representing an implied equity value of approximately $1.7 billion. The transaction wi
15-12G - CTI BIOPHARMA CORP (0000891293) (Filer)
EFFECT - CTI BIOPHARMA CORP (0000891293) (Filer)
EFFECT - CTI BIOPHARMA CORP (0000891293) (Filer)
FLORHAM PARK, N.J., June 03, 2022 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity"), a clinical-stage biotechnology company developing placental-derived off-the-shelf allogeneic cell therapies, today announced the appointment of Diane Parks to its Board of Directors. Ms. Parks, an executive with deep experience in the commercialization of novel immuno-oncology therapies, has led the successful launch of numerous hematology and cancer therapies at large pharmaceutical and biotech companies, including Kite Pharma, Inc. (now part of Gilead Sciences, Inc.), Amgen Inc., and Genentech, Inc. (now part of Roche Holdings, Inc.). "It is with great pleasure we welcome Diane to the Cel
SEATTLE, Aug. 24, 2021 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) today announced the appointment of Diane Parks to its Board of Directors. Ms. Parks has overseen the launch of numerous hematology and cancer therapies at large pharmaceutical and biotech companies, including Kite Pharma, Amgen, and Genentech. "Diane is an accomplished leader with considerable experience driving the successful planning, launch, and commercialization of new medicines in hematology and oncology," said Laurent Fischer, M.D., Chairman of the Board of CTI Biopharma. "We are pleased to have Diane join CTI's Board of Directors at this pivotal time as we advance our JAK2/IRAK-1 inhibitor pacritinib towards a po